![conference banner](/images/conference-banner.jpeg)
Abstract
Chitosan nanogels present a very interesting combination of valuable characteristics for drug delivery; those derived from their nanometric size, such as, large surface area, rapid stimuli-response, and easy functionalization; and those emerged especially from their biocompatibility, biodegradability and mucoadhesive nature. Due to this, chitosan nanogels have reached a prominent position as nanocarriers and have originated accelerated research worldwide. Diverse methods to prepare chitosan nanogels have been reported, showing a dependence on final swelling, drug encapsulation capability and release properties with different synthesis variables, in such a way that they can be exploited to be modulated. The present review describes the properties of chitosan nanogels, along with the different methods of crosslinking and confining chitosan in nanosized particles, and the various fields of drug delivery where they have been applied. This work aims to emphasize the connection between the characteristics of chitosan and the synthetic variables with the final properties of chitosan nanogels in order to enhance controlled drug loading and a sustained release.
Keywords: Chitosan, nanogels, covalent crosslinking, ionic crosslinking, drug delivery, swelling.
Current Pharmaceutical Design
Title:Covalently and Ionically Crosslinked Chitosan Nanogels for Drug Delivery
Volume: 22 Issue: 22
Author(s): Leyre Pérez-Álvarez, José Manuel Laza and Arturo Álvarez-Bautista
Affiliation:
Keywords: Chitosan, nanogels, covalent crosslinking, ionic crosslinking, drug delivery, swelling.
Abstract: Chitosan nanogels present a very interesting combination of valuable characteristics for drug delivery; those derived from their nanometric size, such as, large surface area, rapid stimuli-response, and easy functionalization; and those emerged especially from their biocompatibility, biodegradability and mucoadhesive nature. Due to this, chitosan nanogels have reached a prominent position as nanocarriers and have originated accelerated research worldwide. Diverse methods to prepare chitosan nanogels have been reported, showing a dependence on final swelling, drug encapsulation capability and release properties with different synthesis variables, in such a way that they can be exploited to be modulated. The present review describes the properties of chitosan nanogels, along with the different methods of crosslinking and confining chitosan in nanosized particles, and the various fields of drug delivery where they have been applied. This work aims to emphasize the connection between the characteristics of chitosan and the synthetic variables with the final properties of chitosan nanogels in order to enhance controlled drug loading and a sustained release.
Export Options
About this article
Cite this article as:
Pérez-Álvarez Leyre, Manuel Laza José and Álvarez-Bautista Arturo, Covalently and Ionically Crosslinked Chitosan Nanogels for Drug Delivery, Current Pharmaceutical Design 2016; 22 (22) . https://dx.doi.org/10.2174/1381612822666160216152008
DOI https://dx.doi.org/10.2174/1381612822666160216152008 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacokinetic Profile of A New Diclofenac Prodrug without Gastroulcerogenic Effect
Drug Metabolism Letters Sigma-1 Receptors: Potential Targets for the Treatment of Substance Abuse
Current Pharmaceutical Design Nano-Neurotherapeutics (NNTs): An Emergent and Multifaceted Tool for CNS Disorders
Current Drug Metabolism Neuropeptides and Gastric Mucosal Homeostasis
Current Topics in Medicinal Chemistry Poly(ADP-Ribose)Polymerase 1 (PARP-1) Activation and Ca<sup>2+</sup> Permeable α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid (AMPA) Channels in Post-Ischemic Brain Damage: New Therapeutic Opportunities?
CNS & Neurological Disorders - Drug Targets Cell Death: Tipping the Balance of Autoimmunity and Tissue Repair
Current Pharmaceutical Design Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer
Current Medicinal Chemistry A Mini Review on the Chemistry and Neuroprotective Effects of Silymarin
Current Drug Targets Recent Advances on the Possible Neuroprotective Activities of Epstein- Barr Virus Oncogene BARF1 Protein in Chronic Inflammatory Disorders of Central Nervous System
Current Neuropharmacology Gabapentin-Mediated Effects on Voltage- and Ligand-Gated Currents
Current Neuropharmacology Neuroprotective Role of Agmatine in Neurological Diseases
Current Neuropharmacology Rosuvastatin may have Neuroprotective Effect on Spinal Cord Ischemia Reperfusion Injury
CNS & Neurological Disorders - Drug Targets Fluorescein Fluorescence Use in the Management of Intracranial Neoplastic and Vascular Lesions: A Review and Report of a New Technique
Current Drug Discovery Technologies Opioids, Sleep, and Sleep-Disordered Breathing
Current Pharmaceutical Design The Effect of Spinal Cord Injury on Beta-Amyloid Plaque Pathology in TgCRND8 Mouse Model of Alzheimer’s Disease
Current Alzheimer Research What We have Learned about Pain from Rodent Models of Arthritis?
Current Rheumatology Reviews Ketamine: New Indications for an Old Drug
Current Drug Targets An Osteoblastic Inflammatory Redox Model, using TNF-a, Glucose and Glucose- Oxidized Low- Density Lipoprotein: Targets for Minocycline
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) The Use of Surface Plasmon Resonance to Study the Interactions of Proteins Involved in Conformational Diseases: Experimental Approaches for New Therapeutical Perspectives
Current Medicinal Chemistry Olfactory Ensheathing Cells Protect Cortical Neuron Cultures Exposed to Hypoxia
CNS & Neurological Disorders - Drug Targets